Definition of response to antiviral therapy in chronic hepatitis C

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 160-167

  Craxï, Antonio ^a,b,c   Cammà, Calogero ^a,b,c   Giunta, Marco ^a,b,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b Istituto di Btetodologie Diagnosliche Aranzate   (Italy)

^c Istituto di Clinica Medica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOCHEMICAL MARKER; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CONFERENCE PAPER; DRUG EFFICACY; DRUG POTENCY; HEPATITIS C; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA ANALYSIS; TREATMENT OUTCOME;

EID: 0033406373     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80394-8     Document Type: Conference Paper

References (94)

1. Tinè F, Magrin S, Craxï A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 1991: 13: 192-199.
2. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis: Effects of dose and duration. Hepatology 1996: 24: 778-789.
3. Cammà C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997: 26: 1187-1199.
4. Lindsay KL. Therapy of chronic hepatitis C: overview. Hepatology 1997: 26: 71S-77S.
5. Craxï A, Almasio P, Schalm S. Evaluation of efficacy of antiviral therapy for chronic hepatitis C: a EUROHEP Consensus Report on response criteria. J Viral Hepat 1996: 3: 273-276.
6. Herson J. The use of surrogate endpoints in clinical trials (an introduction to series of four papers). Stat Med 1989: 8: 403404.
7. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Harter D et al. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology 1998: 28: 1687-1695.
8. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T et al. Effect of daily administration period of natural cr-interferon in patients with chronic hepatitis C. Am J Gastroenterol 1996:91:743-747.
9. Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998: 28: 960-964.
10. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997: 26: 226231.
11. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ et al. Hepatitis C viral dynamics in viro and the antiviral efficacy of interferon-a therapy. Science 1998: 282: 103-107.
12. Bellary S, Smith DG, Bankes P, Harris A, Shayiq R, Black M. High dose interferon a-2b therapy for chronic hepatitis C: An open label study of the response and predictors of response. Am J Gastroenterol 1995: 90: 259-262.
13. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. and Hepatitis Interventional Therapy Group. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N EngI J Med 1998: 339: 1485-1492.
14. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al. and Int Hepatitis Intervention Therapy Group. Randomised trial of interferon cr2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998: 352: 1426-1432.
15. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O and Swedish Study Group. Randomised, doubleblind, placebo-controlled trial of interferon a-2b with and without ribavirin for chronic hepatitis C. Lancet 1998: 351: 83-87.
16. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C et al. and Int. Hepatitis Interventional Therapy Group. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N EngI J Med 1998: 339: 1493-1499.
17. Chayama K, Arasa Y, Koida I, Tsubota A, Saitoh S, Ikeda K et al. Antiviral effect of lymphoblastoid interferon-alpha on hepatitis C virus in patients with chronic hepatitis type C. J Gastroenterol Hepat 1994: 9: 128-133.
18. Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha. Hepatology 1992: 15: 37-41.
19. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term followup of patients with chronic hepatitis C treated with a-interferon. Hepatology 1992: 15: 1013-1016.
20. Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995: 21: 639-644.
21. Kakumu S, Yoshika K, Tanaka K, Higashi Y, Kurokawa S, Hirofuji H et al. Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C. J Med Virol 1993: 41: 65-70.
22. Kleter GEM, Brouwer JT, Heijtink RA, Schalm SV, Quint WGV. Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon. Antimicrob Agents Chemother 1993: 37: 595-597.
23. Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993: 12: 341: 1501-1504.
24. Watanabe S, Kobayashi Y, Konishi M, Yokoi M, Kakehashi R, Kaito M, Suzuki S. Appropriate interferon-alpha therapy for chronic hepatitis C: an assessment by quantitative changes in serum hepatitis C virus-RNA. Int Med 1993: 32: 523-529.
25. Castillo I, Bartolome J, Navas S, Gonzalez S, Herrero M, Carreno V. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1994: 19: 342-346.
26. Reichard O, Foberg U, Frydén, A, Mattsson L, Norkrans G, Sönnerborg A et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferona2b for 60 weeks. Hepatology 1994: 19: 280-285.
27. Saleh MG, Tibbs CJ, Koskinas J, Pereira LMMB, Bomford AB, Portmann BC et al. Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy. Hepatology 1994: 20: 1399-1404.
28. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S et al. Factors predictive of response to interferon-a therapy in hepatitis C virus infection. Hepatology 1994: 19: 1088-1094.
29. Pol S, Jaffredo F, Nalpas B, Sayada C, Berthelot P, Brechot C. Pragmatic monitoring of interferon-a therapy in chronic hepatitis related to hepatitis C virus infection (in press).
30. Shindo M, Arai K, Yoshihiro S, Okuno T. Hepatic hepatitis C virus RNA as a predictor of long-term response to interferontherapy. Ann Intern Med 1995: 122: 586-591.
31. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T et al. Efficacy of interferon alpha therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995: 22: 1351-1354.
32. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-2b. Hepatology 1993: 18: 1300-1305.
33. Picciotto A, Bardellini E, Borzone S, Sinelli N, Bonanni P, Bruzzone B et al. Virological and biochemical responses to interferonalpha in chronic hepatitis C. Lancet 1994: 343: 54-55.
34. Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-a in chronic hepatitis C. Ann Intern Med 1996: 124: 1058-1060.
35. Morisco F, Tuccillo C, Sessa G, lasevoli P, Forestieri MC, Del Vecchio-Blanco G et al. Can chronic HCV infection terminate in patients with chronic active hepatitis long-term responders to interferon therapy? Gastroenterology 1995: 108: A1126.
36. Carreno V, Gerken G, Trépo C, Bar-Meier S, Desmet V, Ryff JC and a Multicenter Study Group. Four years of follow-up (LTFUP) of patients with chronic hepatitis C (CHC) treated with interferon-2a. Hepatology 1995: 22: 173A.
37. Karino Y, Toyota J, Higashino K, Sato T, Ohmura T, Aso K et al. Analysis of prognosis of patients with type C chronic hepatitis who treated with interferon. Hepatology 1995: 22: 177A.
38. Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sônnerborg A et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alpha-2b treatment. Hepatology 1995: 21: 918-922.
39. Takahashi M, Yamada G, Tsugeno H, Endo H, Kishi F, Takatani M et al. Long-term biochemical, virological and histological follow-up in patients with chronic hepatitis C treated with interferon. Hepatology 1995: 22: 174A.
40. Ajello A, Freni MA, Spadaro A, Turiano S, Migliorato D, Ferrau O. Six years follow up of patients with chronic hepatitis C treated with IFN. Proceedings of the IX Triennal International Symposium, Rome 1996; C108.
41. Crax'i A, Di Marco V, Almasio P. Hepatic hepatitis C virus RNA in chronic hepatitis C. Ann Int Med 1996: 124: 72.
42. Vento S, Concia E, Ferraro T. Lack of sustained efficacy of interferon in patients with chronic hepatitis C. N Engl J Med 1996: 334: 1479-1480.
43. Eddy MD, Hasselblad V, Shachter R. Meta-analysis by the confidence profile method. The statistical syntesis of evidence. San Diego: Academic Press; 1992.
44. Eddy MD, Hasselblad V. FastPro. Software for meta-analysis by the confidence profile method. San Diego: Academic Press; 1992.
45. Eddy MD, Hasselblad V, Shachter R. An introduction to a bayesian method for meta-analysis: the confidence profile method. Med Decis Making 1990: 10: 15-23.
46. Camps J, Garcia-Granero M, Riezu-Boj JI, Larrea E, De Alava E, Civeira MP et al. Prediction of sustained remission of chronic hepatitis C after a 12-months course of alfa interferon. J Hepatol 1994:21:4-11.
47. Capra F, Casaril M, Gabrielli GB, Tognella P, Rizzi A, Dolci L et al. of-Interferon in the treatment of chronic viral hepatitis: Effects on fibrogenesis serum markers. J Hepatol 1993: 18: 112118.
48. Craxï A, Di Marco V, Lo lacono O, Almasio P, Bruno R, Cammà C et al. Transfusion-associated chronic hepatitis C: alpha-nl interferon for 6 vs. 12 months. J Hepatol 1996: 24: 539-546.
49. De Alava E, Camps J, Pardo-Minden J, Garcia Granero M, Munoz M, Sola J et al. Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alpha interferon. Liver 1993: 13: 73-79.
50. Gallorini A, Plebani M, Pontisso P, Chemello L, Masiero M, Mantovani G et al. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alpha-2a interferon. Liver 1994: 14: 257-264.
51. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial. Hepatology 1995: 21: 291-297.
52. Lin R, Roach E, Zimmerman M, Strasser S, Farrel GC for the Australia Hepatitis C study group. Interferon alpha-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol 1995: 23: 487-496.
53. Marcellin P, Boyer N, Giostra E, Degott C, Couroucé AM, Dcgos F et al. Recombinant human alpha interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991: 13: 393-397.
54. Mazzella G, Salzetta A, Casanova S, Morelli MC, Villanova N, Minière R et al. Treatment of chronic sporadic-type non-A, nonB hepatitis with lymphoblastoid interferon: Gamma GT levels predictive for response. Dig Dis Sei 1994: 39: 866-870.
55. Sieck JO, Ellis ME, Alfurayh O, Ali MA, AU HA, Ayub A et al. Histologically advanced chronic hepatitis C treated with recombinant alpha-interferon: A randomized placebo-controlled double-blind cross-over study. J Hepatol 1993: 19: 418-423.
56. Donadel E, Pontisso P, Ruvoletto MG, Gerotto M, De Salvo G, Chemello L et al. Characteristics of hepatitis C virus before and after interferon treatment in patients with ongoing viraemia but sustained biochemical response. J Med Virol 1998: 54: 7-11.
57. Larghi A, Tagger A, Crosignani A, Ribero ML, Bruno S, Portera G et al. Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy. J Med Virol 1998: 55: 7-11.
58. Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Yoshii O et al. Long-term prognosis of chronic hepatitis C after treatment with interferon alpha 2b and characterization of incomplete responders. Am J Gastroenterol 1996: 91: 2144-2149.
59. Pontisso P, Bellati G, Brunetto M, Chemello L, Colloredo G, Di Stefano R et al. Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity? Hepatology 1999: 29: 585-589.
60. Zeuzem S, Schmidt JM, Lee JH, Von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alpha on viral turnover. Hepatology 1998: 28: 245252.
61. Di Marco V, Vaccaro A, Ferraro D, Lo lacono O, Parisi P, Di Stefano R et al. Dynamic of response to IFN plus ribavirin in relapsers and non responders with chronic hepatitis C. Hepatology 1998: 28: 714A.
62. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW et al. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 1996: 111: 1307-1312.
63. Karino Y, Toyota J, Sugawara M, Higashino K, Sato T, Ohmura T et al. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am J Gastroenterol 1997: 92: 61-65.
64. Izopet J, Payen JL, Alric L, Sandres K, Charlet JP, Vinel JP et al. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy. J Med Virol 1998: 54: 86-91.
65. Brouwer JT, Nevens F, Kieler B, Elewaut A, Adler M, Brenard R et al. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. J Hepatol 1998: 28: 951-959.
66. Lee WM, Reddy KR, Tong MJ, Black M, Van Leeuwen DJ, Hollinger FB et al. and Consensus Interferon Study Group. Early hepatitis C virus RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology 1998:28:1411-1415.
67. Ampurdanès S, Olmedo E, Maluenda MD, Forns X, Lopez-Labrador FX, Costa J et al. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J Hepatol 1996: 25: 827-832.
68. Damen M, Cuypers HTM, Zaaijer HL, Reesink HW, Schaasberg WP, Gerlich WH et al. International collaborative study on the second EUROHEP HCV-RNA reference panel. J Virol Meth 1996: 58: 175-185.
69. Lelie PN, Cuypers HTM, Van Drimmelen AAJ, Quint WGV and Viral Quality Control Programme, Quality assessment of hepatitis C virus nucleic acid amplification methods - An international proficiency study. Infusionsther Transfusionsmed 1998: 25: 102-110.
70. Trabaud MA, Bailly F, Si-Ahmed SN, Chevallier P, Sepetjan M, Colucci G et al. Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon. J Med Virol 1997:52: 105-112.
71. Albadalejo J, Alonso R, Antinozzi R, Bogard M, Bourgault AM, Colucci G et al. Multicenter evaluation of thé COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol 1998: 36: 862-865.
72. Gretch DR. Diagnostic tests for hepatitis C. Hepatology 1997: 26 (Suppl. 1): 43SJ7S.
73. Gordon SC, Dailey PJ, Silverman AL, Khan BA, Kodali VP, Wilber JC. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology 1998: 28: 1702-1706.
74. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E et al. and MULTIVIRC Group. Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 1998: 27: 1213-1219.
75. Morisco F, Bianco GD, Tuccillo C, Galli C, Cirino S, Caporaso N. Long-term observation of HCV-positive patients with normal ALT values: persistence of a clinically healthy state. Res Virol 1998: 149: 277-282.
76. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997: 26: 1393-1398.
77. Bedossa P, the French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994: 20: 15-20.
78. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997: 349: 825-832.
79. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992: 15: 567-571.
80. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C et al. and Multicenter Study Group. A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995: 332: 1457-1462.
81. Poynard T, Opolon P. Hepatitis C: Somber views of natural history and optimistic views of interferon treatment. Hepatology 1998: 27: 1443-1444.
82. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995: 346: 1051-1055.
83. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997: 26 (Suppl. 1): 57S-61S.
84. Gretch D, Corey L, Wilson J et al. Assessment of hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-b. Hepatology 1994: 18: 1319-1325.
85. Hagiwara H, Hayashi N, Mita E et al. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1992: 17: 550.
86. Lau JYN, Davis GL, Khiffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993: 341: 1501-1504.
87. Bruno S, Manzin A, Bellati G, Crosignani A, Borzio M, Battezzati PM et al. Posttreatment natural history of subjects with chronic hepatitis C (CHC) showing sustained biochemical response (SR) to interferon-(IFN) therapy. Hepatology 1998: 28: 578A.
88. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term followup of patients with chronic hepatitis C treated with a-interferon. Hepatology 1992: 15: 1013-1016.
89. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-a2b. Hepatology 1993: 18: 1300-1305.
90. Reichard O, Glaumann H, Frydèn A, Norkrans G, Schvarcz R, Sönnerborg A et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alpha-2b treatment. Hepatology 1995: 21: 918-922.
91. Marcellin P, Boyer N, Gervais A, Martinet M, Pouteau M, Castelnau C et al. Long-term histologie improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-a therapy. Ann Intern Med 1997: 127: 875-881.
92. Cammà C, Di Marco V, Lo lacono O, Almasio P, Giunta M, Fuschi P et al. Long-term course of interferon treated chronic hepatitis C. J Hepatol 1998: 28: 531-537.
93. Lindsay KL, Mosteller M, Rizzetto M, Davis GL, Opolon P, Goldin R et al. Sustained histologie response is common in the absence of virologie response to interferon therapy for chronic hepatitis C. Gastroenterology 1998: 114: A-3.
94. Shiftman ML, Hofmann CM, Sanyal AJ, Luketic VA, Sterling RK, Ferreira-Gonzalez A et al. The effect of maintenance interferon in chronic HCV non-responders: results of a randomized controlled trial. Gastroenterology 1998: 114: A-3.